Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

unknow

★ 5.0 · 22 reads

Request Code
ZLIB.IO18491005
Published
2022
Pages
1
Language
Unknown